A Phase II Trial of a Personalized, Dose-Intense Administration Schedule of 177Lutetium-DOTATATE in Children With Primary Refractory or Relapsed High-Risk Neuroblastoma–LuDO-N
Fredrik Sundquist, Kleopatra Georgantzi, Kirsten Brunsvig Jarvis, Jesper Brok, Minna Koskenvuo, Jelena Rascon, Max van Noesel, Per Grybäck, Joachim Nilsson, Arthur Braat, Mikael Sundin, Sandra Wessman, Nikolas Herold, Lars Hjorth, Per Kogner, Dan Granberg, Mark Gaze, Jakob Stenman
Forskningsoutput: Tidskriftsbidrag › Artikel i vetenskaplig tidskrift › Peer review
Fingeravtryck
Fördjupa i forskningsämnen för ”A Phase II Trial of a Personalized, Dose-Intense Administration Schedule of 177Lutetium-DOTATATE in Children With Primary Refractory or Relapsed High-Risk Neuroblastoma–LuDO-N”. Tillsammans bildar de ett unikt fingeravtryck.